Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03921684	TitleTrial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients	Phase Phase 2	Date Added 2019-04-19	Location Israel	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs capecitabine, mFOLFOX6, Nivolumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02675946	TitleCGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)	Phase Phase 1	Date Added 2016-02-05	Location California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maryland, United States Massachusetts, United States Nebraska, United States New Jersey, United States North Carolina, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Taiwan	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda	Tags MSS/ MMRp
NCT ID NCT03566355	TitleCurative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer	Phase Not Applicable	Date Added 2018-06-25	Location Korea, Republic of	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03608046	TitleAvelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer	Phase Phase 2	Date Added 2018-07-31	Location Belgium	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Avelumab, Cetuximab Injection, Irinotecan	Tags MSS/ MMRp
NCT ID NCT03638206	TitleAutologous CAR-T/TCR-T Cell Immunotherapy for Malignancies	Phase Phase 1/Phase 2	Date Added 2018-08-20	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs CAR-T cell immunotherapy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03740256	TitleBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors	Phase Phase 1	Date Added 2018-11-14	Location Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs CAdVEC	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03772561	TitlePhase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies	Phase Phase 1	Date Added 2018-12-11	Location Singapore	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs AZD5363+Olaparib+Durvalumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID PG545 (pixatimod) in combination with nivolumab	TitlePG545 (pixatimod) in combination with nivolumab	Phase Phase 1	Date Added 2019-04-26	Location	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04626635	TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors	Phase Phase 1, Phase 2	Date Added 2020-11-12	Location California, United States Colorado, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States France Israel Netherlands Poland Spain Turkey (Türkiye)	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs cemiplimab, REGN7075	Tags MSS/ MMRp
NCT ID NCT04991948	TitleStudy of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2021-08-05	Location Florida, United States Belgium	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs CYAD-101, FOLFOX, Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 61 to 70 of 299 entries